Table 1.

Complement therapies in clinical trials for patients with wAMD [5,148].

Target	Drug	Injection Site	Phase (Name), Trial Number	Status/Outcome
C3	POT-4 (Potentia/Alcon) - Compstatin analog - Peptide	IVT	1 (AsAP) NCT00473928	Completed, Some clinical efficacy and no safety concerns
		IVT	2 (RACE) NCT01157065	Completed, Results from the phase I trial (AsAP) were not replicated
	APL-2 (Apellis) - POT-4 derivative - Pegylated peptide	IVT	1 (AsAP II) NCT02461771	Completed, Unpublished
		IVT	1b/2 NCT03465709	Terminated (sufficient data were collected), Unpublished
CD59	Combination of: AAVCAGsCD59 (Hemera) - Virus (AAV2) encoding soluble human CD59 and an anti-VEGF treatment - Bevacizumab (Avastin) - Ranibizumab (Lucentis) - Aflibercept (Eylea)	IVT	1 NCT03585556	Ongoing, Unpublished
C5	LFG316 (Novartis Pharma AG) - Monoclonal human IgG1 ab	IVT	2 NCT01535950	Completed, Unpublished
		IV	2 NCT01624636	Terminated, Unpublished
	Combination of: ARC1905 (Zimura, IVERIC) - RNA aptamer and Ranibizumab (Lucentis) - Humanized monoclonal Fab-fragment	IVT	1 NCT00709527	Completed, Well-tolerated and no evidence of acute toxicity
		IVT	2a NCT03362190	Completed, Generally well-tolerated. Studies were halted to focus on other studies (e.g., Zimura for GA)
C3/C4	IBI302 - Bispecific decoy receptor fusion protein - Binds and inhibits VEGF, C3b + C4b simultaneously	IVT	1 NCT03814291	Ongoing

IVT, intravitreal. IV, intravenous. AAV, adeno-associated virus. VEGF, vascular endothelial growth factor. GA, geographic atrophy. C3, Complement component 3.